Recent Advances in Retinopathy of Prematurity

Nguyen, Quan Dong; Tawansy, K.A.; Hirose, Tatsuo

doi:10.1097/00004397-200110000-00013

Cited by 8 publications

(5 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Variation among studies in whether one or two eyes were treated made comparisons less relevant, which may reflect the unilateral schedule used in the historically influential Cryo-ROP study. 50 However, Swedish registers indicate that bilateral treatment is common (76% of initial treatments and 97% overall) 47 and that retreatment is more frequent among infants with very low gestational age 51 and those treated exclusively with anti-VEGF. 47 When examining ROP treatment, cost components included staff salaries/time, equipment and maintenance, supplies and staff training.…”

Section: Discussionmentioning

confidence: 99%

Costs associated with retinopathy of prematurity: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

ObjectivesTo review and analyse evidence regarding costs for retinopathy of prematurity (ROP) screening, lifetime costs and resource use among infants born preterm who develop ROP, and how these costs have developed over time in different regions.DesignSystematic review and meta-analysisData sourcesPubMed and Scopus from inception to 23 June 2021.Eligibility criteria for selecting studiesIncluded studies presented costs for ROP screening and the lifetime costs (including laser treatment and follow-up costs) and resource use among people who develop ROP. Studies not reporting on cost calculation methods or ROP-specific costs were excluded.Data extraction and synthesisTwo independent reviewers screened for inclusion and extracted data, including items from a published checklist for quality assessment used for bias assessment, summary and random-effects meta-analysis for treatment costs. Included studies were further searched to identify eligible references and citations.ResultsIn total, 15 studies reported ROP screening costs, and 13 reported lifetime costs (either treatment and/or follow-up costs) for infants with ROP. The range for screening costs (10 studies) was US$5–US$253 per visit, or US$324–US$1072 per screened child (5 studies). Costs for treatment (11 studies) ranged from US$38 to US$6500 per child. Four studies reported healthcare follow-up costs (lifetime costs ranging from US$64 to US$2420, and 10-year costs of US$1695, respectively), and of these, three also reported lifetime costs for blindness (range US$26 686–US$224 295) using secondary cost data. Included papers largely followed the quality assessment checklist items, thus indicating a low risk of bias.ConclusionThe costs of screening for and treating ROP are small compared with the societal costs of resulting blindness. However, little evidence is available for predicting the effects of changes in patient population, screening schedule or ROP treatments.PROSPERO registration numberCRD42020208213.

show abstract

Section: Discussionmentioning

confidence: 99%

Costs associated with retinopathy of prematurity: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Prematurity and low birth weight are recognized as major risk factors for ROP [30][31][32]. The lower the gestational age or birth weight, the higher the risk of developing severe ROP.…”

Section: Discussionmentioning

confidence: 99%

Retinopathy of Prematurity: Incidence and Risk Factors

Verma¹,

Nema²,

Patel³

et al. 2016

IJOES

View full text Add to dashboard Cite

“…Gestational age and birth weight are well known, generally accepted major risk factors for ROP: the lower the gestational age or birth weight, the higher the risk of the disease [15][16][17] . The third major risk factor, number and volume of erythrocyte transfusions, has also been reported before to be an independent risk factor for ROP [18][19][20] .…”

Section: Discussionmentioning

confidence: 99%

Can Screening for Retinopathy of Prematurity Be Reduced?

Termote

Donders²,

Schalij‐Delfos³

et al. 2005

Neonatology

View full text Add to dashboard Cite

Background:Asscreening for retinopathy of prematurity (ROP) is costly, time-consuming for the ophthalmologist and discomforting for the neonate, the minimum number of infants should be screened for ROP, without missing infants with severe ROP, at risk for threshold ROP. Objectives:To develop a diagnostic screening guideline for ROP that would safely reduce the number of ROP screening funduscopies in our department. Methods: Data of 275 infants admitted between 1996 and 2000 and screened for ROP according to our Dutch National guideline were studied. Significant risk factors for ROP were calculated, using logistic regression analysis and used to develop a guideline. The discriminative power of the guideline was evaluated using the area under the curve for the receiver operating characteristic curve. Results: Significant risk factors for ROP were: gestational age, birth weight and number of erythrocyte transfusions within the first 4 weeks of life. The combination of these 3 factors resulted in the highest area under the curve: 0.793. Using these 3 factors, a diagnostic screening guideline for ROP was developed: if birth weight + 2 × (gestational age – 20) – 6 × erythrocyte transfusion value within the first 4 weeks of life ≧34, no screening for ROP is necessary. Using this guideline, 22.2% of the infants of the study group could have been excluded from screening; 3.8% of the infants with ROP stages 1–2 would have been missed. Conclusion: In our department, ROP screening can be safely reduced using our diagnostic screening guideline.

show abstract

Recent Advances in Retinopathy of Prematurity

Cited by 8 publications

References 73 publications

Costs associated with retinopathy of prematurity: a systematic review and meta-analysis

Costs associated with retinopathy of prematurity: a systematic review and meta-analysis

Retinopathy of Prematurity: Incidence and Risk Factors

Can Screening for Retinopathy of Prematurity Be Reduced?

Contact Info

Product

Resources

About